profit from every $100 of sales.
$0$100
Medline
$39.47-1.28% today
-5.2% in 1 year
1-year low $31.641-year high $49.99
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
You pay $44.82 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Medline sold, what it kept, and what it did with the cash.
Sales went from $23.2 billion in 2023 to $28.4 billion in 2025, with $1.16 billion of profit last year.
SalesProfit
Medline handed back more cash to shareholders than it generated last year.
Buybacks $2.0B$518M
Free cash flow 2025$1.3B
Bought back its own shares$2.0B
Paid as dividends$518M
Cash vs. debt$1.9B vs. $12.6B
Medline vs. similar companies
Medline grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Medline | 44.8× · Expensive | ||
 Intuitive Surgical | 53.8× · Expensive | ||
 EssilorLuxottica Société anonyme | 36.1× · Expensive | ||
 Becton, Dickinson and | 35.4× · Expensive | ||
 HOYA | 39.3× · Expensive |
AI analysis
An AI analyst reads Medline's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 23,231 | 25,507 | 28,432 | |
| 5,885 | 6,976 | 7,518 | |
| 1,250 | 2,146 | 2,212 | |
| – | – | 3,071 | |
| – | – | 1,159 | |
| – | – | -0.01 | |
| 25.3% | 27.3% | 26.4% | |
| 5.4% | 8.4% | 7.8% | |
| – | – | 4.1% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | – | 35,978 | 38,484 |
| Cash | 1,585 | 199 | 1,939 |
| Total debt | – | 16,494 | 12,627 |
| Total liabilities | – | 19,454 | 19,198 |
| – | – | 10,737 | |
| – | – | 810 | |
| – | – | 7.0% | |
| – | – | 10.8% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 1,685 | 1,769 | 1,744 | |
| 275 | 354 | 447 | |
| 1,410 | 1,415 | 1,297 | |
| Dividends paid | – | – | 518 |
| – | – | 2,003 | |
| 78 | 61 | 76 |
Valuation
- 44.8×
- 27.0×
- –
- 5.1×
- 1.8×
- 40.0×
- 20.4×
- 2.5%
- 2.2%
- 0.0%
Profitability
- 26.4%
- 7.8%
- 4.1%
- 10.9%
- 7.1%
- 7.1%
- 7.6%
- 3.0%
- 6.2%
- –
Growth
- +10.6%
- –
- +24.1%
- –
- −23.8%
Financial health
- 3.5×
- 1.18
- 32.6%
- 2.5×
- 4.29
- 2.37
- 0.74
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 42%of 952
Bottom 44%of 884
Bottom 28%of 601
Top 49%of 886
Top 39%of 987
What analysts expect
- Average price target
- $48.82
- Range
- $38.00 – $60.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.33 | 0.30 | +11.8% |
| Feb 25, 2026 | 0.22 | 0.24 | −7.6% |
| Nov 4, 2025 | 0.31 | – | – |
News
Medline to construct new distribution facility near DetroitSeeking Alpha · Oct 16, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
40No pass
Philip Fisher
32No pass
Peter Lynch
46No pass
Joel Greenblatt
5No pass
Charlie Munger
27No pass
Terry Smith
34No pass
Questions about Medline
Is Medline a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Medline AI analysis
What does Medline do?
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. It is in Medical Instruments & Supplies, based in Northfield, IL, United States, with 45,000 employees.
Does Medline pay a dividend?
Yes. In 2025 it paid out $518 million in dividends.
Is Medline stock halal?
Yes. Medline passes our halal screen: its business is permitted and its debt is 24% of its market value, under the 30% limit. How we check
How has Medline stock done over the past year?
Down 5.2% over the past twelve months, to $39.47. It traded between $31.64 and $49.99 and is 21.0% below its high.
Who are Medline's competitors?
The largest listed companies in the same industry are Intuitive Surgical, EssilorLuxottica Société anonyme, Becton, Dickinson and and HOYA. The peers table on this page compares their profit, growth and price with Medline's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.